(Q34658267)

3 August 2017

Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy (English)

1 reference

3 August 2017

metastatic breast cancer

1 reference

Y Chavarri-Guerra

1

1 reference

3 August 2017

M J Higgins

2

1 reference

3 August 2017

J Szymonifka

3

1 reference

3 August 2017

T Cigler

4

1 reference

3 August 2017

P Liedke

5

1 reference

3 August 2017

A Partridge

6

1 reference

3 August 2017

J Ligibel

7

1 reference

3 August 2017

S E Come

8

1 reference

3 August 2017

D Finkelstein

9

1 reference

3 August 2017

P D Ryan

10

1 reference

3 August 2017

P E Goss

11

1 reference

3 August 2017

language of work or name

English

0 references

publication date

18 September 2014

1 reference

British Journal of Cancer

3 August 2017

1 reference

3 August 2017

111

1 reference

3 August 2017

11

1 reference

3 August 2017

2046-2050

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2014.502

3 August 2017

0 references

cites work

Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

New strategies in estrogen receptor-positive breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

Estrogen as therapy for breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

Tamoxifen-induced tumor stimulation and withdrawal response

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

Metastatic breast cancer response after Exemestane withdrawal: a case report

7 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.502

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.502

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.502

Letrozole withdrawal response in locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.502

Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.502

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260029

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

26 October 2018

1 reference

12 December 2020

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

12 December 2020

Tamoxifen withdrawal response. Report of a case

1 reference

12 December 2020

Response after withdrawal of tamoxifen and progestogens in advanced breast cancer

1 reference

12 December 2020

Aromatase inhibitor withdrawal response in metastatic breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2014.502

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference